Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
EB-MF-CAR-NK-01
- Development stage
- Phase 2
- Lead developer
- Beijing Biotech
- Modality
- CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies, Lymphokine-Activated Killer Cells → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Locoregional
01
Overview
EB-MF-CAR-NK-01 is an investigational allogeneic chimeric antigen receptor (CAR) natural killer (NK) cell therapy developed by Beijing Biotech. It is engineered to simultaneously target Mesothelin (MSLN), which is highly expressed on tumor cells, and Fibroblast Activation Protein (FAP), which is expressed on tumor-associated stroma. This dual-targeting approach is designed to overcome the immunosuppressive tumor microenvironment and enhance antitumor efficacy in solid tumors. The therapy is currently being evaluated in Phase 1/2 clinical trials for the treatment of unresectable, recurrent, or refractory pleural or peritoneal mesothelioma, administered via locoregional infusion following lymphodepleting chemotherapy with fludarabine and cyclophosphamide.
- Other names
- EB-MF-CAR-NK-01-Beijing BiotechEB-MF-CAR-NK01-Beijing BiotechEB-MF-CAR-NK 01-Beijing Biotech
02
Targets
MesothelinFAP (Fibroblast activation protein alpha)
Beyond the preview
Go deeper on EB-MF-CAR-NK-01.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on EB-MF-CAR-NK-01.